Introduction VV116 is a chemically-modified version of the antiviral remdesivir with oral
bioavailability and potent activity against SARS-CoV-2. Areas Covered The optimal …

Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

Background: Since its initial start in December 2019 at Wuhan, China, the coronavirus
disease 2019 (COVID-19) has been rapidly spreading and labelled as a pandemic by the …

Coronaviruses represent a significant threat to both human and animal health,
encompassing a range of pathogenic strains responsible for illnesses, from the common …

Despite the wide availability of several safe and effective vaccines that can prevent severe
COVID-19 disease, the emergence of SARS-CoV-2 variants of concern (VOC) that can …

Background: Recent trials have highlighted the potential of oral antiviral VV116 in the
treatment of patients with mild COVID-19. However, no comprehensive studies have …

During the ongoing pandemic, providing treatment consisting of effective, low-cost oral
antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling …

Background: A novel coronavirus emerged in Wuhan, Hubei Province, China towards the
end of 2019 (SARS-CoV-2 or COVID-19 virus). Large scale spread within China and …

Summary Background Spread of SARS-CoV-2 led to a global pandemic, and there remains
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …

Recent international epidemics of coronavirus-associated illnesses underscore the urgent
medical and public health need for vaccine development and regulatory body approved …